Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980375 | 0.80 | SSTR4 (0.33) | EPHX1FPR3FPR2 | |
| SCHEMBL3981127 | 0.79 | POLB (0.37) | FPR3FPR2 | |
| SCHEMBL3981066 | 0.79 | POLB (0.41) | EPHX1FPR3FPR2 | |
| SCHEMBL3981834 | 0.78 | POLB (0.40) | EPHX1FPR3FPR2 | |
| SCHEMBL3979934 | 0.78 | POLB (0.40) | EPHX1FPR3FPR2 | |
| SCHEMBL6268429 | 0.77 | EPHX1 (0.41) | EPHX1TRPM8 | |
| SCHEMBL3983179 | 0.76 | FPR3 (0.34) | FPR3FPR2 | |
| SCHEMBL3989924 | 0.76 | FPR3 (0.34) | FPR3FPR2 | |
| SCHEMBL3983139 | 0.76 | FPR3 (0.34) | FPR3FPR2 | |
| SCHEMBL6813554 | 0.76 | FPR3 (0.38) | FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | claimed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-8487133-B2 | Substituted bicyclo [4.1.0] heptane-7-carboxylic acid amides and derivatives thereof as food flavor substances | SYMRISE AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487133-B2 | Substituted bicyclo [4.1.0] heptane-7-carboxylic acid amides and derivatives thereof as food flavor substances | SYMRISE AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20100189863-A1 | SUBSTITUTED BICYCLO [4.1.0] HEPTANE-7-CARBOXYLIC ACID AMIDES AND DERIVATIVES THEREOF AS FOOD FLAVOR SUBSTANCES | SYMRISE GMBH & CO.KG (DE) | 2010-07-29 | — | — | US | disclosed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008046895-A1 | SUBSTITUTED BICYCLO[4.1.0]HEPTANE-7-CARBOXYLIC ACID AMIDES AND DERIVATIVES THEREOF AS FOOD FLAVOR SUBSTANCES | SYMRISE GMBH & CO. KG (DE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | EPHX1 1196/4885FPR3 588/4885FPR2 507/4885 |
| US-20100189863-A1 | SUBSTITUTED BICYCLO [4.1.0] HEPTANE-7-CARBOXYLIC ACID AMIDES AND DERIVATIVES THEREOF AS FOOD FLAVOR SUBSTANCES | HCAR3, TAS2R1, HCAR1 | EPHX1 2180/4885FPR3 344/4885FPR2 504/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | EPHX1 1196/4885FPR3 588/4885FPR2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.